Dermata Therapeutics Stock Probability of Future Stock Price Finishing Over 9.15
| DRMA Stock | USD 1.14 0.01 0.87% |
Dermata |
Dermata Therapeutics Target Price Odds to finish over 9.15
The tendency of Dermata Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 9.15 or more in 90 days |
| 1.14 | 90 days | 9.15 | close to zero percent |
Based on a normal probability distribution, the odds of Dermata Therapeutics to move over $ 9.15 or more in 90 days from now is close to zero percent (This Dermata Therapeutics probability density function shows the probability of Dermata Stock to fall within a particular range of prices over 90 days) . Probability of Dermata Therapeutics price to stay between its current price of $ 1.14 and $ 9.15 at the end of the 90-day period is about 91.92 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.6 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Dermata Therapeutics will likely underperform. Additionally Dermata Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Dermata Therapeutics Price Density |
| Price |
Predictive Modules for Dermata Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Dermata Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Dermata Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Dermata Therapeutics is not an exception. The market had few large corrections towards the Dermata Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Dermata Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Dermata Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.62 | |
β | Beta against Dow Jones | 1.60 | |
σ | Overall volatility | 0.25 | |
Ir | Information ratio | -0.07 |
Dermata Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Dermata Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Dermata Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Dermata Therapeutics generated a negative expected return over the last 90 days | |
| Dermata Therapeutics has high historical volatility and very poor performance | |
| Dermata Therapeutics may become a speculative penny stock | |
| Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics currently holds about 10.63 M in cash with (6.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.05. | |
| Dermata Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Increases Stake in Dermata Therapeutics Inc |
Dermata Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Dermata Stock often depends not only on the future outlook of the current and potential Dermata Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dermata Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 195 K | |
| Cash And Short Term Investments | 7.4 M |
Dermata Therapeutics Technical Analysis
Dermata Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Dermata Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Dermata Therapeutics. In general, you should focus on analyzing Dermata Stock price patterns and their correlations with different microeconomic environments and drivers.
Dermata Therapeutics Predictive Forecast Models
Dermata Therapeutics' time-series forecasting models is one of many Dermata Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Dermata Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Dermata Therapeutics
Checking the ongoing alerts about Dermata Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Dermata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Dermata Therapeutics generated a negative expected return over the last 90 days | |
| Dermata Therapeutics has high historical volatility and very poor performance | |
| Dermata Therapeutics may become a speculative penny stock | |
| Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics currently holds about 10.63 M in cash with (6.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.05. | |
| Dermata Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Increases Stake in Dermata Therapeutics Inc |
Check out Dermata Therapeutics Backtesting, Dermata Therapeutics Valuation, Dermata Therapeutics Correlation, Dermata Therapeutics Hype Analysis, Dermata Therapeutics Volatility, Dermata Therapeutics History as well as Dermata Therapeutics Performance. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.36) | Return On Assets (0.91) | Return On Equity (1.73) |
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.